News

Home - News

2025 FDA Inspection

WuXi AppTec’s Changzhou and Taixing API Sites Successfully Pass FDA Inspections

Shanghai, China – April 1, 2025 — WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences industry, today…

WuXi AppTec’s Couvet Site Receives EcoVadis 2024 Silver Medal Rating

Couvet, Switzerland – November 14, 2024 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries,…

WuXi AppTec Opens New R&D Center in Changzhou, China

First operational building dedicated to API development for oligonucleotides, peptides, and complex synthetic conjugates. New facility enhances the Company’s drug substance process R&D capacity to drive innovation across all synthetic modalities and…

WuXi AppTec Breaks Ground on New Site in Singapore to Better Support Global Customers

Photo caption (from left to right): Ms. Cindy Koh, Executive Vice President, Singapore Economic Development Board; Dr. Minzhang Chen, Co-CEO, WuXi AppTec; Mr. Heng Swee Keat, Deputy Prime Minister; Dr. Ge Li,…

A Successful PAI for a new Peptide Drug from Japan PMDA

Our peptide manufacturing facility at Changzhou site has successfully passed the Pre-Approval Inspection by Japan Pharmaceuticals and Medical Devices Agency (PMDA) for an innovative peptide drug. The 3-day inspection, without any major…

2024 CDMO Leadership Awards

Exciting moment! We’ve been honored with the 2024 CDMO Leadership Awards in all six core categories: Capabilities, Compatibility, Expertise, Quality, Reliability, and Service, again! Dr. Jinling Chen, our Senior Vice President and…

Scroll to Top
Please enable JavaScript in your browser to complete this form.
Checkboxes